- Home
- SOR vs TRDA Comparison
SOR vs TRDA Comparison
Compare SOR & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- TRDA
- Stock Information
- Founded
- SOR 1968
- TRDA 2016
- Country
- SOR United States
- TRDA United States
- Employees
- SOR N/A
- TRDA 183
- Industry
- SOR Investment Managers
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- TRDA Health Care
- Exchange
- SOR Nasdaq
- TRDA Nasdaq
- Market Cap
- SOR 368.0M
- TRDA 378.0M
- IPO Year
- SOR N/A
- TRDA 2021
- Fundamental
- Price
- SOR $46.99
- TRDA $10.15
- Analyst Decision
- SOR
- TRDA Strong Buy
- Analyst Count
- SOR 0
- TRDA 2
- Target Price
- SOR N/A
- TRDA $24.50
- AVG Volume (30 Days)
- SOR 16.2K
- TRDA 295.8K
- Earning Date
- SOR 01-01-0001
- TRDA 11-06-2025
- Dividend Yield
- SOR 7.24%
- TRDA N/A
- EPS Growth
- SOR N/A
- TRDA N/A
- EPS
- SOR 6.50
- TRDA N/A
- Revenue
- SOR N/A
- TRDA $61,520,000.00
- Revenue This Year
- SOR N/A
- TRDA N/A
- Revenue Next Year
- SOR N/A
- TRDA N/A
- P/E Ratio
- SOR $6.41
- TRDA N/A
- Revenue Growth
- SOR N/A
- TRDA N/A
- 52 Week Low
- SOR $36.41
- TRDA $4.93
- 52 Week High
- SOR $42.75
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- SOR 66.23
- TRDA 78.06
- Support Level
- SOR $45.30
- TRDA $8.17
- Resistance Level
- SOR $47.39
- TRDA $9.12
- Average True Range (ATR)
- SOR 0.83
- TRDA 0.73
- MACD
- SOR 0.14
- TRDA 0.20
- Stochastic Oscillator
- SOR 83.69
- TRDA 87.12
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.